# EDGAR Filing Document

**Accession Number:** 0001559053
**File Stem:** 0001559053-23-000007
**Filing Date:** 2023-3
**Character Count:** 6325
**Document Hash:** f4bdc20aa2fa635c1bb35a1867cd6c41
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001559053-23-000007.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001559053-23-000007

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230310

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PROTHENA CORP PUBLIC LTD CO
- **CENTRAL INDEX KEY:** 0001559053
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35676
- **FILM NUMBER:** 23723672

**BUSINESS ADDRESS:**
- **STREET 1:** 77 SIR JOHN ROGERSON'S QUAY, BLOCK C
- **STREET 2:** GRAND CANAL DOCKLANDS
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60
- **BUSINESS PHONE:** 011-353-1-236-2500

**MAIL ADDRESS:**
- **STREET 1:** 77 SIR JOHN ROGERSON'S QUAY, BLOCK C
- **STREET 2:** GRAND CANAL DOCKLANDS
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Prothena Corp plc
- **DATE OF NAME CHANGE:** 20121102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neotope Corp Ltd
- **DATE OF NAME CHANGE:** 20120926

?xml version="1.0" ? prta-20230310

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

_______________________________________________________

**FORM 8-K** 

_______________________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 10, 2023** 

_______________________________________________________

**PROTHENA CORPORATION PUBLIC LIMITED COMPANY**

**(Exact name of registrant as specified in its charter)**

_______________________________________________________

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Ireland** | **001-35676** | **001-35676** | **001-35676** | **98-1111119** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission<br>File Number)** | **(Commission<br>File Number)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |
|  | **77 Sir John Rogerson's Quay, Block C** | **77 Sir John Rogerson's Quay, Block C** | **77 Sir John Rogerson's Quay, Block C** |  |
|  | **Grand Canal Docklands** | **Grand Canal Docklands** | **Grand Canal Docklands** |  |
|  | **Dublin 2,** | **D02 VK60,** | **Ireland** |  |
| **(Address of principal executive offices, including Zip Code)** | **(Address of principal executive offices, including Zip Code)** | **(Address of principal executive offices, including Zip Code)** | **(Address of principal executive offices, including Zip Code)** | **(Address of principal executive offices, including Zip Code)** |

---

**Registrant's telephone number, including area code: 011-353-1-236-2500**

___________________________________________________

**(Former Name or Former Address, if Changed Since Last Report.)** 

___________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| <u>Title of Each Class</u> | <u>Trading Symbol</u> | <u>Name of Each Exchange on Which Registered</u> |
| Ordinary Shares, par value $0.01 per share | PRTA | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company ☐

------

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure** |

---

*&nbsp;&nbsp;&nbsp;&nbsp;*

Prothena Corporation plc (the "Company") informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank.

The information in this Item 7.01 is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in Item 7.01 of this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

**SIGNATURES**

&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | March 10, 2023 | **PROTHENA CORPORATION PLC** | **PROTHENA CORPORATION PLC** |
|  |  | By: | /s/ Tran B. Nguyen |
|  |  | Name: | Tran B. Nguyen |
|  |  | Title: | Chief Financial Officer and Chief Strategy Officer |

---